Ignite Creation Date:
2025-12-17 @ 8:00 PM
Ignite Modification Date:
2025-12-24 @ 8:40 AM
Study NCT ID:
NCT00786318
Status:
WITHDRAWN
Last Update Posted:
2017-09-25
First Post:
2008-11-05
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Ziprasidone vs Standard Therapy for Agitated Patients in the ED
Sponsor:
George Washington University
Organization:
Study Overview
Official Title:
Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department
Status:
WITHDRAWN
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Sponsor terminated
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to determine if ziprasidone is superior to standard therapies in the emergency department treatment of the acutely agitated patient. The primary outcome will be the length of time taken until the patient is ready to be evaluated by the psychiatric service, or until a disposition is made.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: